HAO1 · GalNAc, SC
Lumasiran (Oxlumo)
An approved siRNA therapeutic silencing HAO1, indicated for Primary hyperoxaluria type 1. This page lists what the siRNA Atlas corpus holds on Lumasiran and links to each primary document.
Identity
- Generic name
- Lumasiran
- Brand name
- Oxlumo
- Molecular target
- HAO1
- Indication
- Primary hyperoxaluria type 1
- Delivery
- GalNAc, SC
- FDA application
- NDA 214103
- Regulatory coverage
- FDA and EMA
Source documents in the corpus (4)
- FDAFDA prescribing information (current label)
- FDAFDA review
- EMAEMA public assessment report (EPAR)
- EMAEMA product information (SmPC)
Every answer about Lumasiran is drawn from these documents and the indexed literature, and cites the passage it used. Tables inside them are preserved, so numeric dosing, exposure and toxicology values stay searchable.
Ask the corpus about Lumasiran
- →What is the approved dose and dosing interval of lumasiran (Oxlumo)?
- →Describe the clinical pharmacology and ADME of lumasiran.
- →What did the regulatory reviews conclude about the nonclinical safety of lumasiran?
- →Summarise the pivotal trial evidence for lumasiran.
- →How does lumasiran silence HAO1, and how long does the effect last?
Other approved siRNA therapeutics
Information here is drawn from public regulatory records for reference and research. It is not medical advice — verify any clinical or regulatory decision against the current label and assessment report linked above.